Compare Fabrinet (FN) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fabrinet vs Natera Inc. Common Stock — how do they compare? Fabrinet trades at $380.94 (market cap $14.08B), while Natera Inc. Common Stock trades at $392.78 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 4.1× Fabrinet's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Fabrinet nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Fabrinet for 31 Days and Natera Inc. Common Stock for 0 Days on average.
| FN | NTRA | |
|---|---|---|
Market Cap | $14.08B | $57.03B |
Volume | 1,319,574 | 1,131,157 |
Sector | Technology | Health |
52-Week High | $746.47 | $425.64 |
52-Week Low | $374.91 | $179.42 |
Typical Hold Time | 31 Days | 0 Days |
Enterprise Value | $13.21B | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FN trades at $427.82, down 6.26% over 24 hours, with a bullish technical signal despite near-term moving average weakness. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $4.10 exceeding expectations. Revenue grew to $3.42 billion in 2025, with net income of $332.53 million, and is projected to reach $4.6 billion in 2026. Analyst sentiment is positive, with 75% recommending Buy.
Outlook remains favorable due to surging AI data center demand and capacity expansion, though risks include customer concentration and high capital expenditures. The consensus price target of $769.50 implies significant upside, but investors should monitor margin pressures and competitive dynamics in the optical manufacturing sector.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Fabrinet
Fabrinet provides advanced optical and electromechanical manufacturing services to original equipment manufacturers. It specializes in complex products for telecom, automotive, and medical industries.
Read more on FN →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
